Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03949621 · ClinicalTrials.gov registry record · Phase 1
A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT03949621 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 24 participants.
The verdict
NCT03949621, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the PK of single dose of vedolizumab SC 108 milligram (mg) administered as PFS vs investigational device.
Interventions
- DRUG Vedolizumab SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-02-06 |
| Est. Completion | 2018-08-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03949621
The ClinicalTrials.gov registry entry for NCT03949621 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vedolizumab SC is the first listed.
NCT03949621 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03949621 about?
NCT03949621 is a clinical study titled "A Study to Compare the Pharmacokinetics (PK) of Single Subcutaneous (SC) Injections of Vedolizumab Administered in Prefilled Syringe (PFS) Versus (vs) Prefilled Syringe in Needle Safety Device (PFS+NSD) in Healthy Participants". The purpose of this study is to compare the PK of single dose of vedolizumab SC 108 milligram (mg) administered as PFS vs investigational device.
What is the current status of trial NCT03949621?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2018-02-06. Estimated completion is 2018-08-13.
What interventions are being tested in trial NCT03949621?
The interventions under investigation include: Vedolizumab SC (DRUG).
Who is sponsoring clinical trial NCT03949621?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.